Furthermore, we evaluated the involvement of ERLIN2 in breast cancer therapy resistance by treating ERLIN2 knockdown and control SUM225 cells with the anticancer drug Bortezomib [42]. This evidence concerns the gene ERLIN2 and breast carcinoma.